HDAC-IN-94

• Description:

  HDAC-IN-94 is a potent, selective HDAC6 inhibitor (IC50 = 4.5 nM) . HDAC-IN-94 shows >1000-fold selectivity over HDAC8 and shows minimal activity against other isoforms (HDAC1-3/10) . HDAC-IN-94 induces α-tubulin hyperacetylation, apoptosis, and G2/M cell cycle arrest, exhibiting potent anti-tumor efficacy with low cytotoxicity. HDAC-IN-94 can be used for neuroblastoma and glioblastoma research[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Caspase; HDAC; Microtubule/Tubulin

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Smiles:

  O=C(NCC1=CC=C(C(NO)=O)C=C1)/C=C/C2=CC(OC)=C(O)C=C2

• Molecular Formula:

  C18H18N2O5

• Molecular Weight:

  342.35

• References & Citations:

  [1]Cursaro I, et al. New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells. Bioorg Chem. 2025 Oct 14;166:109085.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC5; HDAC6; HDAC8